Cyclooxygenase inhibitors and cardiovascular risk

JAMA. 2007 Feb 14;297(6):586-7; author reply 587-8. doi: 10.1001/jama.297.6.586-b.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Anti-Inflammatory Agents, Non-Steroidal / metabolism
  • Aryl Hydrocarbon Hydroxylases / genetics
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / genetics
  • Celecoxib
  • Cyclooxygenase 2 Inhibitors / adverse effects*
  • Cyclooxygenase 2 Inhibitors / metabolism
  • Cytochrome P-450 CYP2C9
  • Humans
  • Pyrazoles / adverse effects*
  • Pyrazoles / metabolism
  • Risk
  • Sulfonamides / adverse effects*
  • Sulfonamides / metabolism

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Pyrazoles
  • Sulfonamides
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Celecoxib